INMUNE BIO, INC. STOCK ISSUANCE AGREEMENTStock Issuance Agreement • April 9th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
This Stock Issuance Agreement (this “Agreement”) is entered into as of October 3, 2017 (the “Execution Date”), by and between Inmune Bio Inc., a Nevada corporation (the “Company”), and Xencor, Inc., a Delaware corporation (“Xencor”), and is intended by the parties to satisfy certain of the Company’s obligations to Xencor under Section 4.1 of the License Agreement (as defined below) between the Company and Xencor. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to such terms in the License Agreement.
INMUNE BIO, INC. FIRST AMENDMENT TO STOCK ISSUANCE AGREEMENTStock Issuance Agreement • April 9th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This amendment (this “Amendment”) dated as of August 27, 2018 to the Stock Issuance Agreement dated as of October 3, 2017 (the “Agreement”) by and among INmune Bio, Inc., a Nevada corporation (the “Company”), and Xencor, Inc., a Delaware corporation (“Xencor”), hereby amends the Agreement, effective as of the date hereof. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the Agreement.
